This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frank Gawin, MD; Margaret Compton, MS; Robert Byck, MD
Departments of Psychiatry and Pharmacology Yale University School of Medicine 34 Park St New Haven, CN 06519

Arch Gen Psychiatry. 1989;46(3):288-289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

There are no universally accepted treatments of tobacco smoking. We treated with buspirone in an open, uncontrolled six-week trial without psychologic interventions eight smokers who smoked over 1.5 packs of cigarettes per day for over five years. All subjects had attempted to stop smoking, without success. None of the subjects met DSM-III-R criteria for an anxiety disorder. All subjects completing the six-week trial had substantial reductions in smoking.

Buspirone was selected because it, like nicotine, is a nonsedative antianxiety agent and so might oppose the characteristic anxiety, irritability, and fatigue of tobacco withdrawal. Buspirone acts after one to three weeks, causes no sedation, and has no abuse liability.¹ Nicotine activates and may chronically affect central dopaminergic systems^2-3 associated with reward and pleasure. Buspirone also augments dopaminergic transmission, but less directly, via selective blockade of inhibitory dopamine autoreceptors.⁴ Thus, both clinical and perhaps neurochemical . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?